Does This RNAi Play Belong In Your Portfolio?

Deep dive investment analysis of the small RNAi concern, Dicerna Pharmaceuticals, whose stock has been on the move.

Overview

Dicerna Pharmaceuticals (DRNA) is a Watertown, Massachusetts based clinical-stage biopharmaceutical company that was founded in 2006 and came public in early 2014. Dicerna is designing drugs to improve the lives of patients suffering from diseases involving the liver, which includes rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna Pharmaceuticals trades at just under $15.00 a share and has an approximate market cap of $775 million.

Comments

Stories

Fresh Conversations